Lyra Therapeutics Ratios (2021-2025) | LYRA

Ratios Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Profitability
EBT Margin (Quarter) -78,964.29%-5,024.72%-2,545.09%-2,736.38%-4,113.09%-129,290.91%-3,961.22%-3,407.42%-2,874.08%-10,369.18%-4,217.67%-8,046.66%-6,085.13%-5,250.24%-4,668.31%-4,062.84%-23,924.00%-99,271.43%
EBIT Margin (Quarter) -79,150.00%-5,032.47%-2,548.08%-2,742.86%-4,129.81%-137,772.73%-4,222.68%-3,603.28%-3,093.20%-11,285.62%-4,421.80%-8,189.63%-6,380.51%-5,458.37%-4,831.15%-4,822.95%-24,948.00%-101,685.71%
EBITDA Margin (Quarter) -78,964.29%-5,024.72%-2,545.09%-2,736.38%-4,113.09%-129,318.18%-3,970.00%-3,413.32%-2,873.35%-10,353.42%-4,221.80%-8,053.51%-6,076.41%-5,262.68%-4,670.49%-4,063.93%-23,936.00%-99,300.00%
Operating Margin (Quarter) -79,150.00%-5,032.47%-2,548.08%-2,742.86%-4,129.81%-137,772.73%-4,222.68%-3,603.28%-3,093.20%-11,285.62%-4,421.80%-8,189.63%-6,380.51%-5,458.37%-4,831.15%-4,822.95%-24,948.00%-101,685.71%
Net Margin (Quarter) -78,964.29%-5,024.72%-2,545.09%-2,736.38%-4,113.09%-129,290.91%-3,964.63%-3,410.04%-2,877.02%-10,380.82%-4,220.30%-8,048.66%-6,088.72%-5,253.11%-4,670.49%-4,063.93%-23,936.00%-99,300.00%
FCF Margin (Quarter) -68,414.29%-5,030.63%-2,563.68%-1,596.76%-3,057.38%-110,836.36%-3,876.83%-3,133.84%-2,574.63%-13,474.66%-4,286.65%-3,293.48%-9,515.38%-5,403.83%-4,831.69%-3,601.09%-29,444.00%-88,028.57%
Efficiency
Assets Average (Quarter) 74.62M72.05M61.31M51.11M88.69M124.75M114.72M101.92M109.77M123.12M131.59M142.06M118.05M86.67M72.55M61.33M54.44M48.14M39.91M
Equity Average (Quarter) 62.52M52.34M40.75M28.79M64.75M99.74M86.99M73.42M82.33M91.41M86.83M83.46M54.24M25.80M16.11M7.73M2.74M-1.36M-7.52M
Invested Capital (Quarter) 67.55M57.50M47.19M34.32M23.26M106.25M93.22M80.75M66.09M98.58M84.24M89.42M77.50M30.98M20.62M11.59M3.87M1.60M-4.33M-10.72M
Asset Utilization Ratio (Quarter) 0.000.010.010.010.010.010.010.010.010.010.020.020.020.020.010.010.01
Leverage & Solvency
Equity Ratio (Quarter) 0.930.750.700.630.490.820.780.730.700.780.700.630.550.330.260.170.070.03-0.10-0.30
Valuation
Enterprise Value (Quarter) -69.05M-46.08M-34.08M-122.42M-111.31M-99.29M-84.11M-78.42M-103.94M-104.14M-89.09M-69.50M-53.62M-40.58M-31.73M-29.78M-22.05M-15.89M
Return Ratios
Return on Sales (Quarter) -789.64%-50.25%-25.45%-27.36%-41.13%-1,292.91%-39.65%-34.10%-28.77%-103.81%-42.20%-80.49%-60.89%-52.53%-46.70%-40.64%-239.36%-993.00%
Return on Capital Employed (Quarter) -1.01%-1.64%-0.65%-0.49%-0.56%-0.70%-0.67%-0.63%-0.60%-0.59%-1.07%-1.41%-1.61%-1.64%-0.96%-0.91%-1.02%
Return on Invested Capital (Quarter) -0.77%-0.88%-1.95%-3.93%-5.98%-10.56%-15.18%25.90%4.13%
Return on Assets (Quarter) -0.71%-0.93%-0.57%-0.44%-0.48%-0.58%-0.55%-0.50%-0.48%-0.48%-0.86%-1.13%-1.29%-1.30%-0.71%-0.68%-0.72%
Return on Equity (Quarter) -1.07%-1.65%-0.79%-0.55%-0.64%-0.81%-0.74%-0.68%-0.72%-0.83%-1.87%-3.78%-5.80%-10.28%-14.19%24.15%3.84%